Print

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

Purpose

ADNI3 (Alzheimer's Disease Neuroimaging Initiative 3) is the fourth wave of a North American multicenter observational study launched in 2004, sponsored by the National Institute on Aging and the National Institutes of Health. The primary goal of this study is to discover, optimize, standardize, and validate clinical biomarkers used in Alzheimer's disease research and clinical trials. This study seeks to enroll individuals ages 55-90, willing and able to undergo yearly test procedures including cognitive tests, questionnaires, brain imaging, blood draws, and spinal taps. Eligible individuals may have normal cognition with no memory concerns, or have memory concerns and diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease. Participants will be evaluated on a yearly basis, for 2 to 4 years. To learn more, please call Celine Ossinalde at (310) 794-6191 or send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it..

Sponsor: University of Southern California
ClinicalTrials.gov Identifier: NCT02854033

Condition:
Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Length of Study: Participants will be evaluated on a yearly basis, for 2 to 4 years.
Eligibility
Ages Eligible for Study: 55 Years to 90 Years
Genders Eligible for Study: Both

Contact: Celine Ossinalde at (310) 794-6191 or This email address is being protected from spambots. You need JavaScript enabled to view it. to participate in this study or for more information.